BBVA's Latest Setback Leaves Analysts Split Over Sabadell Deal
Spain's decision to delay a possible merger of BBVA SA with Banco Sabadell SA is leaving analysts divided over whether the deal will still go ahead.
The government's announcement on Tuesday that the two banks would have to keep their operations separate for as long as five years has dented expectations of quick cost savings. BBVA has said it's evaluating the impact of the new hurdles.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
43 minutes ago
- Yahoo
A Look At The Fair Value Of Straumann Holding AG (VTX:STMN)
Using the 2 Stage Free Cash Flow to Equity, Straumann Holding fair value estimate is CHF87.37 Straumann Holding's CHF105 share price indicates it is trading at similar levels as its fair value estimate The CHF126 analyst price target for STMN is 44% more than our estimate of fair value Today we will run through one way of estimating the intrinsic value of Straumann Holding AG (VTX:STMN) by taking the expected future cash flows and discounting them to their present value. One way to achieve this is by employing the Discounted Cash Flow (DCF) model. There's really not all that much to it, even though it might appear quite complex. We would caution that there are many ways of valuing a company and, like the DCF, each technique has advantages and disadvantages in certain scenarios. If you still have some burning questions about this type of valuation, take a look at the Simply Wall St analysis model. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. We're using the 2-stage growth model, which simply means we take in account two stages of company's growth. In the initial period the company may have a higher growth rate and the second stage is usually assumed to have a stable growth rate. To start off with, we need to estimate the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years. Generally we assume that a dollar today is more valuable than a dollar in the future, so we discount the value of these future cash flows to their estimated value in today's dollars: 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 Levered FCF (CHF, Millions) CHF478.9m CHF540.7m CHF598.3m CHF534.4m CHF592.6m CHF600.1m CHF606.1m CHF611.1m CHF615.5m CHF619.3m Growth Rate Estimate Source Analyst x8 Analyst x9 Analyst x7 Analyst x1 Analyst x1 Est @ 1.26% Est @ 1.01% Est @ 0.83% Est @ 0.71% Est @ 0.62% Present Value (CHF, Millions) Discounted @ 4.6% CHF458 CHF494 CHF522 CHF446 CHF473 CHF457 CHF442 CHF426 CHF410 CHF394 ("Est" = FCF growth rate estimated by Simply Wall St)Present Value of 10-year Cash Flow (PVCF) = CHF4.5b The second stage is also known as Terminal Value, this is the business's cash flow after the first stage. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country's GDP growth. In this case we have used the 5-year average of the 10-year government bond yield (0.4%) to estimate future growth. In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 4.6%. Terminal Value (TV)= FCF2034 × (1 + g) ÷ (r – g) = CHF619m× (1 + 0.4%) ÷ (4.6%– 0.4%) = CHF15b Present Value of Terminal Value (PVTV)= TV / (1 + r)10= CHF15b÷ ( 1 + 4.6%)10= CHF9.4b The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is CHF14b. In the final step we divide the equity value by the number of shares outstanding. Compared to the current share price of CHF105, the company appears around fair value at the time of writing. Remember though, that this is just an approximate valuation, and like any complex formula - garbage in, garbage out. We would point out that the most important inputs to a discounted cash flow are the discount rate and of course the actual cash flows. If you don't agree with these result, have a go at the calculation yourself and play with the assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Straumann Holding as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 4.6%, which is based on a levered beta of 0.971. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business. See our latest analysis for Straumann Holding Strength Debt is not viewed as a risk. Weakness Earnings growth over the past year underperformed the Medical Equipment industry. Dividend is low compared to the top 25% of dividend payers in the Medical Equipment market. Opportunity Annual earnings are forecast to grow faster than the Swiss market. Good value based on P/E ratio compared to estimated Fair P/E ratio. Threat Revenue is forecast to grow slower than 20% per year. Valuation is only one side of the coin in terms of building your investment thesis, and it shouldn't be the only metric you look at when researching a company. The DCF model is not a perfect stock valuation tool. Rather it should be seen as a guide to "what assumptions need to be true for this stock to be under/overvalued?" For example, changes in the company's cost of equity or the risk free rate can significantly impact the valuation. For Straumann Holding, we've put together three fundamental factors you should consider: Financial Health: Does STMN have a healthy balance sheet? Take a look at our free balance sheet analysis with six simple checks on key factors like leverage and risk. Future Earnings: How does STMN's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart. Other Solid Businesses: Low debt, high returns on equity and good past performance are fundamental to a strong business. Why not explore our interactive list of stocks with solid business fundamentals to see if there are other companies you may not have considered! PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the SWX every day. If you want to find the calculation for other stocks just search here. — Investing narratives with Fair Values A case for TSXV:USA to reach USD $5.00 - $9.00 (CAD $7.30–$12.29) by 2029. By Agricola – Community Contributor Fair Value Estimated: CA$12.29 · 0.9% Overvalued DLocal's Future Growth Fueled by 35% Revenue and Profit Margin Boosts By WynnLevi – Community Contributor Fair Value Estimated: $195.39 · 0.9% Overvalued Historically Cheap, but the Margin of Safety Is Still Thin By Mandelman – Community Contributor Fair Value Estimated: SEK232.58 · 0.1% Overvalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Yahoo
an hour ago
- Yahoo
Tilray Brands, Inc. (TLRY) Stock Declines While Market Improves: Some Information for Investors
Tilray Brands, Inc. (TLRY) closed the most recent trading day at $0.40, moving -2.84% from the previous trading session. The stock fell short of the S&P 500, which registered a gain of 0.52% for the day. Meanwhile, the Dow gained 1%, and the Nasdaq, a tech-heavy index, added 0.52%. The company's shares have seen a decrease of 11.24% over the last month, not keeping up with the Medical sector's gain of 3.5% and the S&P 500's gain of 5.95%. Analysts and investors alike will be keeping a close eye on the performance of Tilray Brands, Inc. in its upcoming earnings disclosure. On that day, Tilray Brands, Inc. is projected to report earnings of -$0.03 per share, which would represent year-over-year growth of 25%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $254.8 million, up 10.84% from the year-ago period. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$1.01 per share and revenue of $850.75 million, indicating changes of -206.06% and 0%, respectively, compared to the previous year. Investors should also pay attention to any latest changes in analyst estimates for Tilray Brands, Inc. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability. Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Currently, Tilray Brands, Inc. is carrying a Zacks Rank of #3 (Hold). The Medical - Products industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 164, placing it within the bottom 34% of over 250 industries. The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Keep in mind to rely on to watch all these stock-impacting metrics, and more, in the succeeding trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Tilray Brands, Inc. (TLRY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
an hour ago
- Yahoo
Albemarle (ALB) Exceeds Market Returns: Some Facts to Consider
Albemarle (ALB) closed at $64.95 in the latest trading session, marking a +1.88% move from the prior day. The stock's performance was ahead of the S&P 500's daily gain of 0.52%. Meanwhile, the Dow gained 1%, and the Nasdaq, a tech-heavy index, added 0.52%. Coming into today, shares of the specialty chemicals company had gained 10.89% in the past month. In that same time, the Basic Materials sector gained 4.06%, while the S&P 500 gained 5.95%. Analysts and investors alike will be keeping a close eye on the performance of Albemarle in its upcoming earnings disclosure. The company's earnings report is set to go public on July 30, 2025. The company is predicted to post an EPS of -$0.76, indicating a 2000% decline compared to the equivalent quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $1.21 billion, showing a 15.52% drop compared to the year-ago quarter. For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$1.67 per share and a revenue of $4.86 billion, representing changes of +28.63% and -9.54%, respectively, from the prior year. Investors should also pay attention to any latest changes in analyst estimates for Albemarle. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability. Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 8.44% downward. Right now, Albemarle possesses a Zacks Rank of #3 (Hold). The Chemical - Diversified industry is part of the Basic Materials sector. With its current Zacks Industry Rank of 222, this industry ranks in the bottom 10% of all industries, numbering over 250. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Don't forget to use to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Albemarle Corporation (ALB) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
